SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company")

Confirmation of Directorate Appointments

27 April 2022 - SkinBioTherapeutics plc (AIM: SBTX), a life Science business focusing on skin health, today announces that further to the announcement of 28 March 2022, the proposed appointments of Manprit Singh Randhawa as full time Chief Financial Officer (CFO) and Danielle Bekker as non-executive director have been approved by the Company's AIM Nominated Adviser.

Danielle Bekker will commence in the role of non-executive director immediately while Manprit Randhawa will commence his appointment by 1 June 2022. Doug Quinn will continue as CFO until Manprit is appointed, stepping down from the board with effect 1 May 2022.

Manprit Singh Randhawa, aged 39, holds or has held in the past 5 years the following directorships and partnerships:

Danielle Bekker, aged 45, holds or has held in the past 5 years the following directorships and partnerships:

Save as disclosed above, no further information is required to be disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies.

-Ends-

For more information please contact:

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.

The Company is targeting a number of skin healthcare sectors, the most advanced of which are cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin axis. In each area SkinBioTherapeutics plans to exemplify its technology through human studies. The Company's first product, AxisBiotix-Ps™, a food supplement to address the symptoms of mild to moderate psoriasis was launched on 29 October - World Psoriasis Day.

The Company listed on AIM in April 2017 and is based in Manchester, UK. For more information, visit: www.skinbiotix.com.